Pop Icon Diagnosed With Cancer at 37 Hospitalized 6 Weeks After Surgery
Pop star Jessie J had a bit of a setback in her cancer journey. On August 3, she shared an update on her health after being admitted to the hospital.
"Not expected or planned. I had and still have symptoms that pointed towards a blood clot on the lung. IT IS NOT A BLOOD CLOT THANK GOD," Jessie J wrote on her Instagram Stories, sharing a photo of her arm with IVs.
"They ran a lot of tests, which ended up showing | have an infection (still trying to figure out what) and a little fluid on my lungs. Finding it hard to breathe in, but I discharged myself last night (I hate being in hospital) and will continue the investigation as an outpatient," she added.
Jessie J was diagnosed with breast cancer at 37. She underwent surgery to remove her tumor in June.
In a subsequent post on August 3, Jessie J said that the hardest part of her journey so far was the day she went in for surgery."The recovery physically is far from quick or easy, and mentally it's been the most challenging time for me. Especially as a Mum with a toddler and being unable to be the mother I usually am. And having to change the plans for my career for this year has been frustrating after working so hard to get to this point and excited to do it all," she said.
Though she made it clear that she was grateful that her surgery was a success, she admitted that the goodness didn't take away from the tough recovery process.
In a third post from her hospital bed, Jessie J took a minute to reflect, reminding herself to "slow" down.
"As an ADHD Aries fire breathing dragon t rex, I can do it myself, I'm always ok woman. That slow pace has been a hard reality to accept tbh. I love moving and working and being up and active but I can't be right now, and that's what it is," she wrote.
"And I am finding the strength in knowing that all can be adjusted to align with a slower pace and the support of my very small inner support circle," she added.
Pop Icon Diagnosed With Cancer at 37 Hospitalized 6 Weeks After Surgery first appeared on Parade on Aug 3, 2025
This story was originally reported by Parade on Aug 3, 2025, where it first appeared.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
Nxera Launches Broad Proprietary Pipeline Targeting Obesity and Chronic Weight Management
Pipeline led by a new proprietary oral small molecule GLP-1 agonist and six additional innovative programs targeting the GIP, Amylin and Apelin receptors, aiming to transform treatment landscape Designed to address emerging areas of patient need, including long-term weight management, co-morbid metabolic disorders, and muscle preservation during weight loss Tokyo, Japan and Cambridge, UK, 6 August 2025 – Nxera Pharma Co., Ltd. ('Nxera'; TSE: 4565) a technology-powered biopharmaceutical company, today announces the launch of a broad new pipeline strategically focused on advancing next-generation therapies for obesity and associated metabolic disorders. Independent to the productive drug discovery collaborations with Pfizer and Eli Lilly, Nxera has established, expanded and accelerated drug discovery efforts of its own proprietary pipeline across a broad range of validated GPCR targets in these major disorders. Chris Cargill, President and CEO of Nxera, commented: 'Nxera scientists were among the pioneers in elucidating the structure of the GLP-1 receptor and other key receptors being targeted, giving us a clear advantage in developing potentially best-in-class next generation drug candidates. For the past 12 months, Nxera scientists have been advancing a broad metabolic disease pipeline to capitalize independently on our differentiated science. Today, we reveal the addition of these programs to our discovery portfolio, and are confident in achieving significant progress over the mid-term, delivering clear value for shareholders and patients in the rapidly expanding obesity market, projected to exceed US$100 billion annually in global sales.' Central to Nxera's pipeline is its new, wholly owned oral small molecule GLP-1 agonist program, focussed on differentiated chemistry, which is distinct, independent and developed separately from Pfizer's PF-06954522, allowing Nxera full control to drive rapid progress. Complementing this program, Nxera is simultaneously accelerating the advancement of an additional six established GPCR-targeted programs focused on obesity and chronic weight management: Three small molecule agonist programs (GIP, Apelin, Amylin) One small molecule antagonist program (GIP) Two long-acting programs (targets undisclosed) Nxera's pipeline leverages its proprietary NxWave™ GPCR-focused structure-based design platform to rapidly identify unique, highly differentiated lead molecules with novel chemistry. This process utilizes Nxera's NxHit proprietary small molecule libraries and NxStaR proteins for DNA encoded library (DEL) screening, distinguishing these candidates from others currently in discovery and clinical development globally. Nxera's focused approach is designed to deliver highly effective therapies addressing critical patient needs: Long-term weight maintenance: Convenient, scalable oral therapies for sustained weight loss. Targeting key obesity-related co-morbidities: Enhanced outcomes in cardiovascular, renal, and liver diseases, with new therapeutic indications emerging continuously. Reducing side effects and broadening out to difficult to treat populations: Targeted treatments for elderly, post-menopausal, and sarcopenic populations. Backed by an expert team with deep experience in GPCR drug discovery, Nxera is strategically positioned to be a leader in developing the next generation of best-in-class obesity and metabolic therapies. Nxera maintains its strong commitment to other key therapeutic areas including neurology, gastroenterology, and immunology, continuing to leverage the NxWave™ platform's proven capabilities in these domains. Separately, Nxera notes that Pfizer yesterday discontinued development of its Phase 1 candidate PF-06954522, a separate small molecule GLP-1 agonist, which was discovered under a strategic drug discovery collaboration with Nxera. This discontinuation by Pfizer was due to a portfolio decision and not because of any adverse safety findings. Nxera intends to enter discussions with Pfizer regarding potential opportunities to advance GLP-1 molecules discovered by Pfizer under the collaboration. Nxera will announce its earnings results and present operational highlights for Q2 2025 on Friday, 8 August 2025. –END– About Nxera PharmaNxera Pharma is a technology powered biopharma company in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. We have built an agile, new-generation commercial business in Japan to develop and commercialize innovative medicines, including several launched products, to address this high value, large and growing market and those in the broader APAC region. Behind that, and powered by our unique NxWave™ discovery platform, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnership with leading pharma and biotech companies. This pipeline of potentially first- and best-in-class candidates is focused on addressing major unmet needs in some of the fastest-growing areas of medicine across obesity and metabolic disorders, neurology/neuropsychiatry and immunology and inflammation. Nxera employs approximately 400 talented people at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565). For more information, please visit LinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma Enquiries: Nxera – Media and Investor RelationsShinya Tsuzuki, VP, Head of Investor RelationsShinichiro Nishishita, VP Investor Relations, Head of Regulatory DisclosuresMaya Bennison, Communications Manager+81 (0)3 5962 5718 | +44 (0)1223 949390 |IR@ MEDiSTRAVA (for International Media)Mark Swallow, Frazer Hall, Erica Hollingsworth+44 (0)203 928 6900 | Nxera@ Forward-looking statementsThis press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Nxera Pharma Group's actual results to differ materially from those expressed or implied by the forward looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or in to access your portfolio
CNN
9 minutes ago
- CNN
4 killed in medical transport plane crash on Navajo Nation, tribal authorities say
Four people were killed Tuesday when a medical transport plane crashed on Navajo Nation land in Arizona, according to tribal police. 'The small aircraft was enroute to pick up a patient from a nearby hospital, when the crash occurred,' Navajo Nation Police said on Facebook. The accident took place around 12:40 p.m. near Chinle, Arizona, according to police. 'We extend our deepest condolences to their family and loved ones during this time,' Navajo Police said. The plane was a Beechcraft 300, the National Transportation Safety Board said. 'NTSB investigators are en route to the scene (and) expected to start arriving tonight. Once on site, the investigators will begin the process of documenting the scene and examining the aircraft. The aircraft will then be recovered to a secure facility for further evaluation,' Sarah Taylor Sulick, a spokesperson for the NTSB, told CNN. CNN has reached out to the medical transport company for comment.
Fox News
17 minutes ago
- Fox News
Biden's doctor thought cognitive tests were 'meaningless,' ex-aide Bruce Reed told investigators
Former White House physician Kevin O'Connor previously dismissed cognitive tests as "meaningless," ex-Biden administration aide Bruce Reed told House investigators on Tuesday, according to a source familiar with the proceedings. Reed, who served as White House deputy chief of staff for policy, is the ninth member of former President Joe Biden's inner circle to sit down with House Oversight Committee lawyers. A source familiar with his interview told Fox News Digital that Reed attributed Biden's disastrous 2024 debate performance against then-candidate Donald Trump to the former president's stutter, a condition that's been well-documented and Biden himself has publicly acknowledged. But his meandering and seemingly tired demeanor on stage with Trump alarmed both Democrats and media pundits, who saw it as a glaring sign of Biden's advanced age. It precipitated both a public and private push by left-wing lawmakers to get Biden to drop out of the race – which he did in July 2024. When asked whether public concerns about Biden's mental acuity were legitimate, however, the source told Fox News Digital that Reed said he believes Americans should not have had any concerns about the ex-president's mental faculties. Reed also told investigators that "the president's communications team anticipated that the issue of a cognitive test would likely be raised" in Biden's interview with ABC News host George Stephanopoulos following the debate. "Mr. Reed further explained that President Biden's physician, Dr. Kevin O'Connor, dismissed cognitive tests as 'meaningless,'" the source said. O'Connor was among the first former White House officials summoned by House investigators, and sat down with them last month after being compelled via subpoena. But his sit-down lasted less than an hour, with the doctor opting to invoke the Fifth Amendment to avoid answering all questions but his name. His lawyers said at the time that was due to concerns about violating doctor-patient confidentiality. In his own interview Tuesday, Reed also defended the Biden 2024 campaign's preference to hold the debate earlier than typical for a presidential cycle, the source said. "During his interview, Mr. Reed stated that the decision to hold the debate early was a deliberate strategy to get ahead of early voting and the Olympics. He emphasized that the campaign's push for the early debate was unrelated to concerns about President Biden's age," the source said. Excerpts of Reed's opening statement to investigators, obtained by Fox News Digital via a second source familiar with the interview, show he emphatically defended Biden's cognitive abilities. "While I can only speak to my own observations, I had the benefit of working with President Biden nearly every day of his presidency. Despite his age, President Biden maintained an unrelenting work ethic, embraced complex policy issues, and approached decisions with diligence and deliberation," Reed said, according to the source. Reed also described Biden as "a demanding boss who routinely grilled staff members on a topic until he reached the limits of our knowledge so he could judge whether to have confidence in our advice," though "that didn't mean he'd take it." "From the first days in the White House to the last, President Biden governed the same way he'd gotten there, by trusting his own values and instincts," Reed said, according to the source. "There is no tougher test than the presidency: President Biden asked tough questions, made tough decisions, and led his country well in challenging times for the nation and the world." Chairman James Comer, R-Ky., is probing whether Biden's senior aides worked to cover up evidence of mental decline in the former president, and whether that meant Biden was not making the final decision on executive matters signed by autopen. Of particular interest to Comer is the myriad of clemency orders Biden signed in the latter half of his presidency, though the former president told The New York Times last month that he was behind every decision. His allies have also dismissed Comer's probe as purely political. Fox News Digital reached out to Reed's counsel and lawyers for O'Connor for comment but did not hear back by press time.
